Zeposia: adverse event reports filed with FDA

8,134

reports as suspect product

0% of all reports · about 1,376 a year

751

reports, 12 months to June 2026

1,294 in the 12 months before

26.5%

marked serious by the reporter

49.1% across the class

1%

record death among outcomes, as reported

84 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Zeposia reports recording the termmedian drug in sphingosine 1-phosphate receptor modulator

1. Fatiguetiredness9.2%751
2. Multiple sclerosis relapsea flare of multiple sclerosis7.1%579
3. Drug ineffectivethe medicine did not work as expected6.5%530
4. Headachehead pain6.2%507
5. Product dose omission issuea dose was missed4.5%363
6. Dizzinesslight-headedness or unsteadiness4.3%346
7. Nauseafeeling sick3.4%278
8. Diarrhoealoose or frequent stools3.2%259
9. Colitis ulcerative3%248
10. Painpain, site not specified3%248
11. Back painback pain2.6%215
12. Adverse eventan unwanted medical event, type not specified2.3%188
13. Falla fall2.2%182
14. Multiple sclerosis2.1%169
15. Dyspnoeashortness of breath1.9%153
16. Hypoaesthesianumbness1.9%151
17. Arthralgiajoint pain1.7%141
18. Hypertensionhigh blood pressure1.7%140
19. Depressionlow mood1.7%136
20. Astheniaweakness or lack of energy1.7%135
21. Covid-19COVID-19 infection1.6%129
22. Gait disturbancedifficulty walking1.5%124
23. Pain in extremitypain in an arm or leg1.5%123
24. Urinary tract infectionbladder or urinary infection1.5%120
25. Off label useused for a purpose or in a way not on the label1.5%118
26. Blood pressure increaseda raised blood pressure reading1.4%117
27. Paraesthesiatingling or pins and needles1.4%117
28. Peripheral swellingswelling of the arms or legs1.4%117
29. Balance disorderproblems with balance1.4%116
30. Lymphocyte count decreased1.4%116

Top 30 of 640 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the sphingosine 1-phosphate receptor modulator class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 103,701 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 94.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 8,134 reports.

Drugs most often listed in the same reports

Other products listed in reports where Zeposia is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the sphingosine 1-phosphate receptor modulator class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zeposia as a suspect or interacting product; reports listing it only as a concomitant medication (115) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.